FMR LLC, together with Abigail P. Johnson, filed Amendment No. 10 to Schedule 13G disclosing an 8.8 % beneficial ownership stake in 10x Genomics (TXG) Class A common stock as of 30 Jun 2025.
The filing reports 9,839,175.62 shares under sole dispositive power and 9,806,070 shares under sole voting power; no shared voting or dispositive power exists. The position includes 892,772 Class B shares held by Fidelity-advised funds that are convertible 1-for-1 into Class A, explaining the fractional share total. Assuming full conversion of all Class B shares outstanding, the reporting persons would own 7.99 % of the resulting Class A float.
FMR LLC is classified as a parent holding company (HC); Johnson is reported in her individual (IN) capacity. The certification states that the stake is held in the ordinary course of business and not for the purpose of influencing control. Signature authority is executed by Richard Bourgelas under power of attorney dated 23 May 2023. No group status or other material exhibits beyond Exhibit 99 (inter-company agreement) are referenced.
Positive
FMR LLC and Abigail P. Johnson report holding 9.84 million TXG shares, representing 8.8 % of Class A common stock
Negative
None.
Insights
TL;DR – FMR still owns 8.8 % of TXG; disclosure is routine and neutral.
FMR’s sizeable position confirms continued institutional sponsorship but offers no insight into direction (increase or decrease). With sole voting/dispositive power, Fidelity can act unilaterally, yet the ownership remains well below the 10 % threshold that could trigger heightened regulatory scrutiny or board influence. The language expressly disclaims any intent to affect control, suggesting a passive stance typical of index or growth mandates. Impact on valuation or governance is therefore minimal; liquidity considerations hinge on future transactions that are not addressed here.
TL;DR – Passive 13G filing; no control intentions disclosed, governance impact limited.
The amendment restates holdings rather than signaling activism. Neither FMR nor Abigail P. Johnson report shared power, group status, or control-oriented objectives. The inclusion of convertible Class B shares clarifies cross-class exposure but doesn’t change voting dynamics. Investors should simply note that a single institution controls nearly one-tenth of the float, a factor in any future proxy matters, though no such agenda is implied here.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
CLASS A COMMON STOCK
(e)
CUSIP No.:
88025U109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
9,839,175.62*
*892,772 of the shares of Class A Common Stock of 10X GENOMICS INC reported as being beneficially owned by the reporting persons at June 30, 2025, are included in this Schedule 13G because the Reporting persons are deemed to beneficially own such shares as a result of the direct ownership of 892,772 shares of Class B Common Stock of 10X GENOMICS INC by investment companies advised by Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management Trust Company, and Strategic Advisers LLC, indirect wholly-owned subsidiaries of FMR LLC as of such date, which shares of Class B Common Stock are convertible into shares of Class A Common Stock at the election of the holder at an exchange rate of 1:1. Such shares of Class B Common Stock represent 7.4144% of the outstanding Class B Common Stock. Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 9,839,175.620 shares of Class A Common Stock reported as being beneficially owned by the reporting persons in this Schedule 13G would represent 7.9906% of the outstanding Class A Common Stock.
(b)
Percent of class:
8.8%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
9,839,175.62*
*892,772 of the shares of Class A Common Stock of 10X GENOMICS INC reported as being beneficially owned by the reporting persons at June 30, 2025, are included in this Schedule 13G because the Reporting persons are deemed to beneficially own such shares as a result of the direct ownership of 892,772 shares of Class B Common Stock of 10X GENOMICS INC by investment companies advised by Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management Trust Company, and Strategic Advisers LLC, indirect wholly-owned subsidiaries of FMR LLC as of such date, which shares of Class B Common Stock are convertible into shares of Class A Common Stock at the election of the holder at an exchange rate of 1:1. Such shares of Class B Common Stock represent 7.4144% of the outstanding Class B Common Stock. Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 9,839,175.620 shares of Class A Common Stock reported as being beneficially owned by the reporting persons in this Schedule 13G would represent 7.9906% of the outstanding Class A Common Stock.
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of 10X GENOMICS INC. No one other person's interest in the CLASS A COMMON STOCK of 10X GENOMICS INC is more than five percent of the total outstanding CLASS A COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
Not applicable.
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
Not applicable.
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Richard Bourgelas
Name/Title:
Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
08/05/2025
Abigail P. Johnson
Signature:
Richard Bourgelas
Name/Title:
Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:
08/05/2025
Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.
